Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors

Rebecca A. Haeusler, Kirsten Hartil, Bhavapriya Vaitheesvaran, Isabel Arrieta-Cruz, Colette M. Knight, Joshua R. Cook, Helene L. Kammoun, Mark A. Febbraio, Roger Gutierrez-Juarez, Irwin J. Kurland and Domenico Accili ()
Additional contact information
Rebecca A. Haeusler: Columbia University
Kirsten Hartil: Albert Einstein University
Bhavapriya Vaitheesvaran: Albert Einstein University
Isabel Arrieta-Cruz: Albert Einstein University
Colette M. Knight: Albert Einstein University
Joshua R. Cook: Columbia University
Helene L. Kammoun: Cellular and Molecular Metabolism Laboratory, Baker IDI Heart and Diabetes Institute
Mark A. Febbraio: Cellular and Molecular Metabolism Laboratory, Baker IDI Heart and Diabetes Institute
Roger Gutierrez-Juarez: Albert Einstein University
Irwin J. Kurland: Albert Einstein University
Domenico Accili: Columbia University

Nature Communications, 2014, vol. 5, issue 1, 1-8

Abstract: Abstract Insulin integrates hepatic glucose and lipid metabolism, directing nutrients to storage as glycogen and triglyceride. In type 2 diabetes, levels of the former are low and the latter are exaggerated, posing a pathophysiologic and therapeutic conundrum. A branching model of insulin signalling, with FoxO1 presiding over glucose production and Srebp-1c regulating lipogenesis, provides a potential explanation. Here we illustrate an alternative mechanism that integrates glucose production and lipogenesis under the unifying control of FoxO. Liver-specific ablation of three FoxOs (L–FoxO1,3,4) prevents the induction of glucose-6-phosphatase and the repression of glucokinase during fasting, thus increasing lipogenesis at the expense of glucose production. We document a similar pattern in the early phases of diet-induced insulin resistance, and propose that FoxOs are required to enable the liver to direct nutritionally derived carbons to glucose versus lipid metabolism. Our data underscore the heterogeneity of hepatic insulin resistance during progression from the metabolic syndrome to overt diabetes, and the conceptual challenge of designing therapies that curtail glucose production without promoting hepatic lipid accumulation.

Date: 2014
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/ncomms6190 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms6190

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms6190

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().